Caxton Corp Cti Biopharma Corp Transaction History

Caxton Corp

  • $18.7 Million
  • Q2 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.9 - $5.23 $4.25 Million - $11.7 Million
-2,239,300 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$1.44 - $2.86 $1.78 Million - $3.54 Million
1,239,300 Added 123.93%
2,239,300 $5.55 Million
Q3 2021

Nov 15, 2021
SELL
$2.25 - $3.18 $2.96 Million - $4.18 Million
-1,314,533 Reduced 56.79%
1,000,000 $2.95 Million
Q2 2021

Aug 16, 2021
SELL
$2.16 - $2.62 $432,246 - $524,298
-200,114 Reduced 7.96%
2,314,533 $5.79 Million
Q1 2021

May 17, 2021
SELL
$2.68 - $3.8 $3.31 Million - $4.69 Million
-1,235,243 Reduced 32.94%
2,514,647 $7.32 Million
Q4 2020

Feb 16, 2021
SELL
$2.48 - $3.8 $1.4 Million - $2.14 Million
-563,727 Reduced 13.07%
3,749,890 $12.1 Million
Q3 2020

Nov 16, 2020
BUY
$1.02 - $2.15 $3.77 Million - $7.94 Million
3,694,157 Added 596.35%
4,313,617 $9.27 Million
Q2 2020

Aug 14, 2020
BUY
$0.88 - $1.32 $2,433 - $3,649
2,765 Added 0.45%
619,460 $719,000
Q1 2020

May 15, 2020
BUY
$0.69 - $1.54 $200,848 - $448,270
291,085 Added 89.4%
616,695 $567,000
Q4 2019

Feb 14, 2020
BUY
$0.72 - $1.64 $306 - $697
425 Added 0.13%
325,610 $514,000
Q3 2019

Nov 14, 2019
BUY
$0.64 - $0.92 $469 - $674
733 Added 0.23%
325,185 $272,000
Q2 2019

Aug 14, 2019
BUY
$0.8 - $1.03 $1,140 - $1,468
1,426 Added 0.44%
324,452 $279,000
Q1 2019

May 14, 2019
BUY
$0.9 - $1.37 $179,176 - $272,746
199,085 Added 160.63%
323,026 $313,000
Q4 2018

Feb 14, 2019
SELL
$0.73 - $2.19 $53,668 - $161,004
-73,518 Reduced 37.23%
123,941 $91,000
Q3 2018

Nov 14, 2018
BUY
$1.72 - $5.24 $339,629 - $1.03 Million
197,459 New
197,459 $427,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Caxton Corp Portfolio

Follow Caxton Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email